"Risk of venous throboembolism due to antipsychotic drugs therapy"@en . "Mal\u00FD, Radovan" . "227236" . "1211-7579" . . . "Riziko \u017Eiln\u00EDho tromboembolizmu p\u0159i l\u00E9\u010Db\u011B antipsychotiky" . . . . "FR - Francouzsk\u00E1 republika" . . "[17ACFF6CCBAE]" . "Z(MSM0021620816), Z(MZ0FNHK2005)" . "V\u00FDskyt \u017Eiln\u00EDho tromboembolizmu (TEN) p\u0159i l\u00E9\u010Db\u011B antipsychotiky je dokumentov\u00E1n ji\u017E od jej\u00EDho po\u010D\u00E1tku, tedy 50. let minul\u00E9ho stolet\u00ED. Zv\u00FD\u0161en\u00E1 pozornost je tomuto probl\u00E9mu v\u011Bnov\u00E1na v posledn\u00EDch deseti letech. D\u016Fkazy zat\u00EDm \u010Derp\u00E1me p\u0159ev\u00E1\u017En\u011B z observa\u010Dn\u00EDch studi\u00ED a kazuistick\u00FDch s\u00E9ri\u00ED. Zv\u00FD\u0161en\u00E9 riziko TEN je spojeno zejm\u00E9na s l\u00E9\u010Dbou klozapinem a n\u00EDzkopotentn\u00EDmi antipsychotiky prvn\u00ED generace, mno\u017E\u00ED se ale zpr\u00E1vy o v\u00FDskytu tohoto ne\u017E\u00E1douc\u00EDho \u00FA\u010Dinku p\u0159i u\u017E\u00EDv\u00E1n\u00ED dal\u0161\u00EDch antipsychotik druh\u00E9 generace (risperidon, olanzapin). Nejvy\u0161\u0161\u00ED riziko patologick\u00E9ho krevn\u00EDho sr\u00E1\u017Een\u00ED se objevuje v prvn\u00EDch 3 m\u011Bs\u00EDc\u00EDch po nasazen\u00ED prepar\u00E1tu. Mezi mo\u017En\u00E9 etiopatogenetick\u00E9 faktory TEN p\u0159i l\u00E9\u010Db\u011B antipsychotiky pat\u0159\u00ED sedace, obezita, elevace hladin antifsosfolipidov\u00FDch protil\u00E1tek, zv\u00FD\u0161en\u00E1 aktivace a agregace desti\u010Dek, hyperhomocysteinemie a hyperprolaktinemie. Ji\u017E samotn\u00E1 diagn\u00F3za schizofrenie a bipol\u00E1rn\u00ED afektivn\u00ED poruchy, hospitalizace nebo stres s aktivac\u00ED sympatiku a zv\u00FD\u0161en\u00EDm hladiny katecholamin\u016F jsou protrombogenn\u00EDmi faktory. Pro objasn\u011Bn\u00ED biologick\u00FDch mechanizm\u016F vztahu antipsychotik a TEN jsou zapot\u0159eb\u00ED prospektivn\u00ED studie." . "Riziko \u017Eiln\u00EDho tromboembolizmu p\u0159i l\u00E9\u010Db\u011B antipsychotiky"@cs . "Venous thromboembolism (VTE) in patients treated with antipsychotic medication has been documented from its beginning in the 1950s. An increased attention has been paid to this topic in the last decade. Recent scientific evidence is mostly based on observational studies and case report series. An increased risk for VTE is associated with therapy with clozapine or low potency first generation antipsychotics. In addition to this, reports on VTE induced by other second generation antipsychotics (olanzapine, risperidon) become more frequent in the literature. The most important risk of a pathological blood clotting occurs in the first three months after the antipsychotic drug is prescribed. Sedation, obesity, antiphospholipid antibodies, increased activation and aggregation of thrombocytes, hyperhomocysteinemia and hyperporlactinemia belong to possible etiopathogenetic factors in venous thromboembolism. The diagnosis of schizophrenia or bipolar affective disorder itself, hospitalization or stress with activation of the sympatic nerve and increase in catecholamine blood level also act as prothrombogenic factors. Prospective studies are necessary to clarify biological mechanisms involved in the association of antipsychotics with venous thromboembolism."@en . . "RIV/00179906:_____/11:10107005" . "15" . . . . "4" . . . "Psychiatrie" . . "Risk of venous throboembolism due to antipsychotic drugs therapy"@en . . . "risk factors; thromboembolism; embolism; thrombosis; antipsychotics"@en . "2"^^ . "Riziko \u017Eiln\u00EDho tromboembolizmu p\u0159i l\u00E9\u010Db\u011B antipsychotiky" . "Masopust, Ji\u0159\u00ED" . . . . "2"^^ . "Riziko \u017Eiln\u00EDho tromboembolizmu p\u0159i l\u00E9\u010Db\u011B antipsychotiky"@cs . "10"^^ . "V\u00FDskyt \u017Eiln\u00EDho tromboembolizmu (TEN) p\u0159i l\u00E9\u010Db\u011B antipsychotiky je dokumentov\u00E1n ji\u017E od jej\u00EDho po\u010D\u00E1tku, tedy 50. let minul\u00E9ho stolet\u00ED. Zv\u00FD\u0161en\u00E1 pozornost je tomuto probl\u00E9mu v\u011Bnov\u00E1na v posledn\u00EDch deseti letech. D\u016Fkazy zat\u00EDm \u010Derp\u00E1me p\u0159ev\u00E1\u017En\u011B z observa\u010Dn\u00EDch studi\u00ED a kazuistick\u00FDch s\u00E9ri\u00ED. Zv\u00FD\u0161en\u00E9 riziko TEN je spojeno zejm\u00E9na s l\u00E9\u010Dbou klozapinem a n\u00EDzkopotentn\u00EDmi antipsychotiky prvn\u00ED generace, mno\u017E\u00ED se ale zpr\u00E1vy o v\u00FDskytu tohoto ne\u017E\u00E1douc\u00EDho \u00FA\u010Dinku p\u0159i u\u017E\u00EDv\u00E1n\u00ED dal\u0161\u00EDch antipsychotik druh\u00E9 generace (risperidon, olanzapin). Nejvy\u0161\u0161\u00ED riziko patologick\u00E9ho krevn\u00EDho sr\u00E1\u017Een\u00ED se objevuje v prvn\u00EDch 3 m\u011Bs\u00EDc\u00EDch po nasazen\u00ED prepar\u00E1tu. Mezi mo\u017En\u00E9 etiopatogenetick\u00E9 faktory TEN p\u0159i l\u00E9\u010Db\u011B antipsychotiky pat\u0159\u00ED sedace, obezita, elevace hladin antifsosfolipidov\u00FDch protil\u00E1tek, zv\u00FD\u0161en\u00E1 aktivace a agregace desti\u010Dek, hyperhomocysteinemie a hyperprolaktinemie. Ji\u017E samotn\u00E1 diagn\u00F3za schizofrenie a bipol\u00E1rn\u00ED afektivn\u00ED poruchy, hospitalizace nebo stres s aktivac\u00ED sympatiku a zv\u00FD\u0161en\u00EDm hladiny katecholamin\u016F jsou protrombogenn\u00EDmi faktory. Pro objasn\u011Bn\u00ED biologick\u00FDch mechanizm\u016F vztahu antipsychotik a TEN jsou zapot\u0159eb\u00ED prospektivn\u00ED studie."@cs . "RIV/00179906:_____/11:10107005!RIV12-MZ0-00179906" . . .